2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.08 Retrospective Analysis of Treatment Outcomes for T-DM1 (Trastuzumab Emtansine) following T-DXd (Trastuzumab Deruxtecan) and T-DXd following T-DM1 in HER2-Mutated Non-Small Cell Lung Cancer

PP01.08 Retrospective Analysis of Treatment Outcomes for T-DM1 (Trastuzumab Emtansine) following T-DXd (Trastuzumab Deruxtecan) and T-DXd following T-DM1 in HER2-Mutated Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The retrospective analysis conducted by Daniel Reinhorn and colleagues at Memorial Sloan Kettering Cancer Center aimed to assess treatment outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received two different HER2-targeted antibody-drug conjugates (ADCs): Trastuzumab deruxtecan (T-DXd) and Trastuzumab emtansine (T-DM1). This is significant as T-DXd is currently the only approved targeted therapy for HER2-mutant NSCLC, and the benefits of using multiple ADCs in treatment sequences are not well understood.<br /><br />The study included 23 patients, with 15 receiving T-DM1 after T-DXd and 8 receiving T-DXd after T-DM1. The cohorts had similar demographic distributions, with the majority of patients being White and significant portions being female.<br /><br />Key findings indicated that T-DM1 following T-DXd resulted in a median progression-free survival (rwPFS) of 4.4 months and a median overall survival (OS) of 6.3 months. In contrast, T-DXd following T-DM1 was associated with a longer median rwPFS of 5.3 months and a notably prolonged median OS of 25 months, suggesting superior outcomes in this sequence.<br /><br />The study concludes that while T-DM1 after T-DXd has limited efficacy in this patient population, T-DXd demonstrates greater effectiveness when administered after T-DM1. These results highlight the need for novel therapies in this clinical context, although it suggests a potential sequence advantage of T-DXd following T-DM1 in improving patient outcomes. The findings warrant further research to explore these therapeutic sequences and their implications for treating HER2-mutant NSCLC.

Asset Subtitle

Daniel Reinhorn

Keywords

HER2-mutant NSCLC

antibody-drug conjugates

Trastuzumab deruxtecan

Trastuzumab emtansine

treatment outcomes

progression-free survival

overall survival

sequence advantage

novel therapies

clinical research